|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:CEP89-BRAF (FusionGDB2 ID:HG84902TG673) |
Fusion Gene Summary for CEP89-BRAF |
Fusion gene summary |
Fusion gene information | Fusion gene name: CEP89-BRAF | Fusion gene ID: hg84902tg673 | Hgene | Tgene | Gene symbol | CEP89 | BRAF | Gene ID | 84902 | 673 |
Gene name | centrosomal protein 89 | B-Raf proto-oncogene, serine/threonine kinase | |
Synonyms | CCDC123|CEP123 | B-RAF1|B-raf|BRAF1|NS7|RAFB1 | |
Cytomap | ('CEP89')('BRAF') 19q13.11 | 7q34 | |
Type of gene | protein-coding | protein-coding | |
Description | centrosomal protein of 89 kDacentrosomal protein 123centrosomal protein 89kDacoiled-coil domain containing 123coiled-coil domain-containing protein 123, mitochondrial | serine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | Q96ST8 | P15056 | |
Ensembl transtripts involved in fusion gene | ENST00000305768, ENST00000590597, ENST00000591863, | ||
Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 48 X 58 X 16=44544 |
# samples | 3 | 69 | |
** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(69/44544*10)=-6.0124909441832 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CEP89 [Title/Abstract] AND BRAF [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | |||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | BRAF | GO:0000186 | activation of MAPKK activity | 29433126 |
Tgene | BRAF | GO:0006468 | protein phosphorylation | 17563371 |
Tgene | BRAF | GO:0010828 | positive regulation of glucose transmembrane transport | 23010278 |
Tgene | BRAF | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
Tgene | BRAF | GO:0043066 | negative regulation of apoptotic process | 19667065 |
Tgene | BRAF | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 22065586 |
Tgene | BRAF | GO:0071277 | cellular response to calcium ion | 18567582 |
Tgene | BRAF | GO:0090150 | establishment of protein localization to membrane | 23010278 |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerKB3 | . | . | CEP89 | chr19 | 33390762 | - | BRAF | chr7 | 140487384 | - |
Top |
Fusion Gene ORF analysis for CEP89-BRAF |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000305768 | ENST00000288602 | CEP89 | chr19 | 33390762 | - | BRAF | chr7 | 140487384 | - |
intron-3CDS | ENST00000590597 | ENST00000288602 | CEP89 | chr19 | 33390762 | - | BRAF | chr7 | 140487384 | - |
intron-3CDS | ENST00000591863 | ENST00000288602 | CEP89 | chr19 | 33390762 | - | BRAF | chr7 | 140487384 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000305768 | CEP89 | chr19 | 33390762 | - | ENST00000288602 | BRAF | chr7 | 140487384 | - | 3243 | 1964 | 89 | 3124 | 1011 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for CEP89-BRAF |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for CEP89-BRAF |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:/chr7:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
CEP89 | BRAF |
FUNCTION: Required for ciliogenesis. Also plays a role in mitochondrial metabolism where it may modulate complex IV activity. {ECO:0000269|PubMed:23348840, ECO:0000269|PubMed:23575228}. | FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CEP89-BRAF |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>15924_15924_1_CEP89-BRAF_CEP89_chr19_33390762_ENST00000305768_BRAF_chr7_140487384_ENST00000288602_length(transcript)=3243nt_BP=1964nt CCTGCGGCGGGCTTTAGGGAGTGGTCCCTGGCTGTGGATAGATCTGCTGATGAGTCCAGGCCCCGGTCCATTCTCCTCGCGCTGCAAGGA TGCTCCTGGGATTTCGGAGAGGCCGCAGGAGTCATTTCAAACACATCATCCATGGCCTTTTACCTGCAGCCAGCGTTGCTCCGAAGGCAG CTGTGCCACGCACACCTCCTCCCCGCAGCCCCAACCCATCTCCAGAGAGACCAAGATCTGCTCTGGCAGCAGCCATTCTGGCGACAACAT TGACTGGGCGGACGGTTGCTATTCCTCAGCCTCGCCAGAGGTCCCGGTCTGAGAGTGATGTGAGCAGTGTTGAACAGGACAGCTTCATCG AGCCCTATGCCACCACCTCACAGCTGAGGCCTCGGCCAAATTGGCAGAGTGAGATGGGAAGAAGATCTTCTTTGCCATCCTTTGAAACAC TGGACTATGGGGACGAAGAGGACATTGAAACTCAGCTGTCATCCAGCGGCAAGGAATTGGGGGATGTCAGTGCCCGGGAGGACAGAGGAG GCCACAGTGATGACCTGTACGCTGTGCCACACAGAAATCAGGTGCCATTGTTACATGAGGTGAACAGTGAAGACGATGAAAATATTTCTC ATCAAGATGGGTTTCCAGGCTCCCCTCCTGCACCACAGCGGACACAACAAAAAGATGGTAAACACCCTGTTCTGAATTTAAAGGATGAAA AACCTCCATTATGTGAGAAACCTCCACCCTCCCCAGATATAACTGGTAGAGCACGTCAAAGATATACAGAAATAACCAGAGAAAAGTTTG AGGCATTAAAAGAAGAAAATATGGACCTAAACAATATGAATCAAAGCCTTACCCTTGAACTAAACACAATGAAACAAGCAATGAAAGAAC TACAGTTAAAACTTAAGGGAATGGAAAAAGAGAAGAGAAAGCTCAAAGAGGCTGAGAAGGCGTCGTCACAGGAAGTTGCTGCACCTGAAT TACTTTATCTGCGAAAACAAGCTCAAGAACTGGTGGATGAAAATGATGGATTGAAAATGACTGTCCATCGTTTGAATGTAGAACTCAGTC GATATCAGACAAAATTCAGGCATTTGTCCAAGGAAGAGAGCTTAAATATTGAAGGCCTCCCATCCAAGGGCCCTATACCACCCTGGTTGT TGGATATAAAGTACCTGTCACCATTGTTGCTGGCTTATGAAGATATGATGAAAGAGAAGGACGAGCTCAATGCCACCCTCAAGGAGGAAA TGAGAATGTTTAGGATGCGAGTCCAAGAAGTGGTGAAAGAAAATGAAGAATTGCACCAAGAGTTAAATAAGAGTAGTGCTGTTACCAGTG AGGAATGGCGTCAGCTTCAGACTCAAGCAAAACTGGTTTTAGAGGAAAACAAGTTGTTGCTGGAGCAGTTGGAGATTCAGCAAAGGAAAG CCAAGGACAGCCACCAGGAGCGCCTCCAAGAAGTTTCTAAGCTGACTAAACAACTAATGCTCCTGGAGGCAAAAACCCACGGCCAGGAAA AGGAGCTGGCGGAGAACAGGGAACAGCTGGAGATTTTACGTGCCAAATGCCAAGAACTCAAAACACACTCGGATGGCAAAATCGCAGTGG AAGTTCATAAATCAATTGTGAATGAATTAAAAAGCCAATTACAGAAGGAAGAAGAGAAAGAAAGGGCTGAGATGGAGGAGTTGATGGAGA AGCTGACAGTCCTGCAAGCGCAGAAGAAGAGCCTGCTGTTAGAGAAGAACAGTTTGACAGAGCAAAACAAAGCACTGGAAGCCGAACTTG AACGAGCACAGAAAATCAATAGGAAATCTCAAAAGAAAATTGAGGTCCTCAAAAAGCAGGTGGAAAAAGCCATGGGGAACGAAATGTCTG CTCATCAGTACCTGGCAAACCTTGTTGGCCTGGCAGAAAACATAACCCAGGAACGTGACAGTCTTATGTGTTTGGACTTGATTAGAGACC AAGGATTTCGTGGTGATGGAGGATCAACCACAGGTTTGTCTGCTACCCCCCCTGCCTCATTACCTGGCTCACTAACTAACGTGAAAGCCT TACAGAAATCTCCAGGACCTCAGCGAGAAAGGAAGTCATCTTCATCCTCAGAAGACAGGAATCGAATGAAAACACTTGGTAGACGGGACT CGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAATTGGATCTGGATCATTTGGAACAGTCTACAAGGGAAAGT GGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTCAGCAGTTACAAGCCTTCAAAAATGAAGTAGGAGTACTCA GGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGCCACAACTGGCTATTGTTACCCAGTGGTGTGAGGGCTCCA GCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAACTTATAGATATTGCACGACAGACTGCACAGGGCATGGATT ACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATATTTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTG GTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTGGATGGCACCAGAAGTCATCA GAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTGGAATTGTTCTGTATGAATTGATGACTGGACAGTTACCTT ATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGATACCTGTCTCCAGATCTCAGTAAGGTACGGAGTAACTGTC CAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATGAGAGACCACTCTTTCCCCAAATTCTCGCCTCTATTGAGC TGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCTTGAATCGGGCTGGTTTCCAAACAGAGGATTTTAGTCTAT ATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGTTTCCTGTCCACTGAAACAAATGAGTGAGAGAGTTCAGGA GAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTAAATTGAATAAAATACTCTCTTTTTTTTTAAGGTGAACCAAA >15924_15924_1_CEP89-BRAF_CEP89_chr19_33390762_ENST00000305768_BRAF_chr7_140487384_ENST00000288602_length(amino acids)=1011AA_BP=625 MLLGFRRGRRSHFKHIIHGLLPAASVAPKAAVPRTPPPRSPNPSPERPRSALAAAILATTLTGRTVAIPQPRQRSRSESDVSSVEQDSFI EPYATTSQLRPRPNWQSEMGRRSSLPSFETLDYGDEEDIETQLSSSGKELGDVSAREDRGGHSDDLYAVPHRNQVPLLHEVNSEDDENIS HQDGFPGSPPAPQRTQQKDGKHPVLNLKDEKPPLCEKPPPSPDITGRARQRYTEITREKFEALKEENMDLNNMNQSLTLELNTMKQAMKE LQLKLKGMEKEKRKLKEAEKASSQEVAAPELLYLRKQAQELVDENDGLKMTVHRLNVELSRYQTKFRHLSKEESLNIEGLPSKGPIPPWL LDIKYLSPLLLAYEDMMKEKDELNATLKEEMRMFRMRVQEVVKENEELHQELNKSSAVTSEEWRQLQTQAKLVLEENKLLLEQLEIQQRK AKDSHQERLQEVSKLTKQLMLLEAKTHGQEKELAENREQLEILRAKCQELKTHSDGKIAVEVHKSIVNELKSQLQKEEEKERAEMEELME KLTVLQAQKKSLLLEKNSLTEQNKALEAELERAQKINRKSQKKIEVLKKQVEKAMGNEMSAHQYLANLVGLAENITQERDSLMCLDLIRD QGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGK WHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMD YLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLP YSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CEP89-BRAF |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CEP89-BRAF |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for CEP89-BRAF |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | C0025202 | melanoma | 24 | CGI;CTD_human;UNIPROT | |
Tgene | C1275081 | Cardio-facio-cutaneous syndrome | 14 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0009402 | Colorectal Carcinoma | 8 | CTD_human;UNIPROT | |
Tgene | C0028326 | Noonan Syndrome | 8 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET | |
Tgene | C0238463 | Papillary thyroid carcinoma | 8 | CTD_human;ORPHANET | |
Tgene | C0040136 | Thyroid Neoplasm | 6 | CGI;CTD_human | |
Tgene | C0151468 | Thyroid Gland Follicular Adenoma | 6 | CTD_human | |
Tgene | C0175704 | LEOPARD Syndrome | 6 | CLINGEN;GENOMICS_ENGLAND | |
Tgene | C0549473 | Thyroid carcinoma | 6 | CGI;CTD_human | |
Tgene | C3150970 | NOONAN SYNDROME 7 | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0009404 | Colorectal Neoplasms | 4 | CTD_human | |
Tgene | C3150971 | LEOPARD SYNDROME 3 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C1519086 | Pilomyxoid astrocytoma | 3 | ORPHANET | |
Tgene | C0004565 | Melanoma, B16 | 2 | CTD_human | |
Tgene | C0009075 | Melanoma, Cloudman S91 | 2 | CTD_human | |
Tgene | C0018598 | Melanoma, Harding-Passey | 2 | CTD_human | |
Tgene | C0023443 | Hairy Cell Leukemia | 2 | CGI;ORPHANET | |
Tgene | C0025205 | Melanoma, Experimental | 2 | CTD_human | |
Tgene | C0033578 | Prostatic Neoplasms | 2 | CTD_human | |
Tgene | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CGI;CTD_human | |
Tgene | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human | |
Tgene | C0587248 | Costello syndrome (disorder) | 2 | CLINGEN;CTD_human | |
Tgene | C3501843 | Nonmedullary Thyroid Carcinoma | 2 | CTD_human | |
Tgene | C3501844 | Familial Nonmedullary Thyroid Cancer | 2 | CTD_human | |
Tgene | C0002448 | Ameloblastoma | 1 | CTD_human | |
Tgene | C0004114 | Astrocytoma | 1 | CTD_human | |
Tgene | C0010276 | Craniopharyngioma | 1 | CTD_human;ORPHANET | |
Tgene | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human | |
Tgene | C0017638 | Glioma | 1 | CGI;CTD_human | |
Tgene | C0019621 | Histiocytosis, Langerhans-Cell | 1 | CGI;ORPHANET | |
Tgene | C0022665 | Kidney Neoplasm | 1 | CTD_human | |
Tgene | C0023903 | Liver neoplasms | 1 | CTD_human | |
Tgene | C0024232 | Lymphatic Metastasis | 1 | CTD_human | |
Tgene | C0024694 | Mandibular Neoplasms | 1 | CTD_human | |
Tgene | C0027659 | Neoplasms, Experimental | 1 | CTD_human | |
Tgene | C0027962 | Melanocytic nevus | 1 | GENOMICS_ENGLAND | |
Tgene | C0036920 | Sezary Syndrome | 1 | CTD_human | |
Tgene | C0041409 | Turner Syndrome, Male | 1 | CTD_human | |
Tgene | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human | |
Tgene | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human | |
Tgene | C0206686 | Adrenocortical carcinoma | 1 | CTD_human | |
Tgene | C0206754 | Neuroendocrine Tumors | 1 | CTD_human | |
Tgene | C0259783 | mixed gliomas | 1 | CTD_human | |
Tgene | C0278875 | Adult Craniopharyngioma | 1 | CTD_human | |
Tgene | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human | |
Tgene | C0280785 | Diffuse Astrocytoma | 1 | CTD_human | |
Tgene | C0334579 | Anaplastic astrocytoma | 1 | CGI;CTD_human | |
Tgene | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human | |
Tgene | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human | |
Tgene | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human | |
Tgene | C0334583 | Pilocytic Astrocytoma | 1 | CGI;CTD_human | |
Tgene | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human | |
Tgene | C0345904 | Malignant neoplasm of liver | 1 | CTD_human | |
Tgene | C0376407 | Granulomatous Slack Skin | 1 | CTD_human | |
Tgene | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND | |
Tgene | C0431128 | Papillary craniopharyngioma | 1 | CTD_human | |
Tgene | C0431129 | Adamantinous Craniopharyngioma | 1 | CTD_human | |
Tgene | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human | |
Tgene | C0555198 | Malignant Glioma | 1 | CTD_human | |
Tgene | C0596263 | Carcinogenesis | 1 | CTD_human | |
Tgene | C0684249 | Carcinoma of lung | 1 | CGI;UNIPROT | |
Tgene | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human | |
Tgene | C0750935 | Cerebral Astrocytoma | 1 | CTD_human | |
Tgene | C0750936 | Intracranial Astrocytoma | 1 | CTD_human | |
Tgene | C0751061 | Craniopharyngioma, Child | 1 | CTD_human | |
Tgene | C0920269 | Microsatellite Instability | 1 | CTD_human | |
Tgene | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human | |
Tgene | C1704230 | Grade I Astrocytoma | 1 | CTD_human | |
Tgene | C1721098 | Replication Error Phenotype | 1 | CTD_human | |
Tgene | C2239176 | Liver carcinoma | 1 | CTD_human | |
Tgene | C4551484 | Leopard Syndrome 1 | 1 | GENOMICS_ENGLAND | |
Tgene | C4551602 | Noonan Syndrome 1 | 1 | CTD_human | |
Tgene | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | UNIPROT | |
Tgene | C4733333 | familial non-medullary thyroid cancer | 1 | GENOMICS_ENGLAND |